GlassScriptPhysician profile
Zihe Shan
NPI 1982662458
$26,587.29
in general payments reported to CMS, 2019-2025
42 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,990 · 2020: $3,388 · 2021: $3,830 · 2022: $3,843 · 2023: $3,696 · 2024: $3,470 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $78.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,458.60 |
| Education | $78.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,263.37 | 2019-2025 | Jardiance, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $3,995.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $2,074.87 | 2019-2023 | |
| Gilead Sciences, INC. | $1,762.96 | 2019-2025 | |
| Lilly USA, LLC | $1,575.11 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $1,511.13 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $1,365.49 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,149.56 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $989.64 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $869.80 | 2019-2025 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $818.49 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $783.17 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Pfizer INC. | $725.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $724.49 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $657.77 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zihe Shan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.